News | August 14, 2022
SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
With this, the company can start selling Ibuprofen in the European markets.
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The inspection concluded with one minor observation in Form 483
The approval by the US FDA comes after extensive safety testing and manufacturing improvements
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
The inspection conducted by EDQM at its Visakhapatnam facility
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Subscribe To Our Newsletter & Stay Updated
